Olga Lamacchia
Overview
Explore the profile of Olga Lamacchia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirijello A, Pacilli G, Siena A, Mangiacotti A, DErrico M, Dilalla D, et al.
Nutr Metab Cardiovasc Dis
. 2024 Nov;
35(1):103768.
PMID: 39561690
Background And Aim: Fibrosis-4 (FIB-4) index is a widely used test for non-invasively assessing liver fibrosis. We aimed to investigate the association between FIB-4 index and risk of all-cause mortality...
2.
Menzaghi C, Marucci A, Mastroianno M, Di Ciaccia G, Armillotta M, Prehn C, et al.
J Clin Endocrinol Metab
. 2024 Aug;
PMID: 39193712
Objective: To study whether inflammation is associated with and helps predict mortality risk in patients with type 2 diabetes. To explore the intertwined link between inflammation and tryptophan metabolism on...
3.
Lamacchia O, Menzaghi C, Copetti M, Mastroianno M, Corsano C, Prehn C, et al.
J Clin Endocrinol Metab
. 2024 Aug;
PMID: 39136240
Context: The independent role of glomerular filtration rate (GFR) decline in shaping the risk of mortality in people with type 2 diabetes has only been partially addressed. Objective: The objective...
4.
Fadini G, Buzzetti R, Pitocco D, Tortato E, Scatena A, Lamacchia O, et al.
Diabetes Obes Metab
. 2024 Feb;
26(5):1746-1756.
PMID: 38327240
Aim: The study was designed to generate real-world evidence on IDegLira in the Italian clinical practice in two groups of patients with type 2 diabetes (T2D), switching to IDegLira either...
5.
Correale M, Mazzeo P, Fortunato M, Paradiso M, Furore A, Fanizzi A, et al.
Clin Physiol Funct Imaging
. 2023 Oct;
44(1):112-117.
PMID: 37795627
Background: SGLT2 inhibitors have been shown to reduce hospitalisation in patients with chronic heart failure (CHF). The cardioprotective mechanisms of gliflozins however have not been fully elucidated. The aim of...
6.
Corsano C, Paradiso M, Laudadio E, Sollitto F, Lamacchia O
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373678
Hypoglycemia in patients without diabetes is a diagnostic challenge for the endocrinologist. Sometimes it is related to rare causes such as Doege-Potter Syndrome (DPS). DPS is caused by an abnormal...
7.
Piscitelli P, DErrico M, Vigna C, Marchese N, Lamacchia O, Fontana A, et al.
Nutr Metab Cardiovasc Dis
. 2023 Jun;
33(8):1591-1598.
PMID: 37263913
Background And Aims: The CHADS-VASc score estimates the risk of cardioembolism in patients with atrial fibrillation (AF). It also predicts vascular events and death in different clinical settings, even in...
8.
Orsi E, Solini A, Penno G, Bonora E, Fondelli C, Trevisan R, et al.
Cardiovasc Diabetol
. 2022 Dec;
21(1):266.
PMID: 36461034
Background: An "obesity paradox" for mortality has been shown in chronic disorders such as diabetes, and attributed to methodological bias, including the use of body mass index (BMI) for obesity...
9.
DErrico M, Piscitelli P, Mirijello A, Santoliquido M, Salvatori M, Vigna C, et al.
Eur J Clin Invest
. 2022 Jul;
52(11):e13830.
PMID: 35778894
Background: The CHA DS -VASc score, widely used to estimate cardioembolic risk in patients with atrial fibrillation (AF), appears to be useful also in predicting vascular adverse events and death...
10.
Morieri M, Lamacchia O, Manzato E, Giaccari A, Avogaro A
Cardiovasc Diabetol
. 2022 May;
21(1):73.
PMID: 35562766
No abstract available.